Literature DB >> 30863948

HULC functions as an oncogene in ovarian carcinoma cells by negatively modulating miR-125a-3p.

Ping Chu1, Lina Xu1, Haiying Su2.   

Abstract

The aberrant expression of highly upregulated in liver cancer (HULC) has been reported to participate in ovarian cancer development. A recent research has revealed that HULC-modulated microRNAs (miRNAs) in tumorigenesis. To confirm the functions of HULC on tumorigenesis of ovarian, we explored the effects of HULC expression on ovarian cancer cell development, as well as the underlying mechanism. We transfected SKOV3 cells with pEX-HULC, sh-HULC, and miR-125a-3p mimic as well as their corresponding negative controls (pEX-3, sh-NC, and NC) to alter the expression of HULC and miR-125a-3p, which were analyzed by quantitative reverse transcription PCR (qRT-PCR). Expression of proteins associated with cell cycle, apoptosis, and signaling pathways was determined by Western blot assay. The proliferation, apoptosis, migration, and invasion were explored by bromodeoxyuridine (BrdU) incorporation assay, Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) method, and transwell migration and invasion assays, respectively. HULC overexpression promoted proliferation, migration, and invasion, while inhibited apoptosis of SKOV3 cells. In addition, HULC negatively regulated the expression of miR-125a-3p. Besides, miR-125a-3p mimic reversed the effects of HULC on proliferation, migration, and invasion as well as apoptosis of SKOV3 cells. Moreover, we found that HULC enhanced phosphorylated expression of regulatory factors in phosphatidylinositol 3 kinase/protein kinase B/mammalian targets of rapamycin (PI3K/AKT/mTOR) signaling pathway by downregulating expression of miR-125a-3p. Overexpression of HULC promoted ovarian carcinoma development by activating PI3K/AKT/mTOR signaling pathway via downregulating miR-125a-3p.

Entities:  

Keywords:  HULC; Ovarian carcinoma; PI3K/AKT/mTOR signaling pathway; miR-125a-3p

Mesh:

Substances:

Year:  2019        PMID: 30863948     DOI: 10.1007/s13105-019-00669-5

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  33 in total

Review 1.  lncRNAs and microRNAs with a role in cancer development.

Authors:  Julia Liz; Manel Esteller
Journal:  Biochim Biophys Acta       Date:  2015-07-04

2.  Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA.

Authors:  Katrin Panzitt; Marisa M O Tschernatsch; Christian Guelly; Tarek Moustafa; Martin Stradner; Heimo M Strohmaier; Charles R Buck; Helmut Denk; Renée Schroeder; Michael Trauner; Kurt Zatloukal
Journal:  Gastroenterology       Date:  2006-08-14       Impact factor: 22.682

3.  Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway.

Authors:  Ming Cui; Zelin Xiao; Yue Wang; Minying Zheng; Tianqiang Song; Xiaoli Cai; Baodi Sun; Lihong Ye; Xiaodong Zhang
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

Review 4.  The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.

Authors:  Seiji Mabuchi; Hiromasa Kuroda; Ryoko Takahashi; Tomoyuki Sasano
Journal:  Gynecol Oncol       Date:  2015-02-10       Impact factor: 5.482

Review 5.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells.

Authors:  Dennis W Stacey
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells.

Authors:  Lili Jiang; Qin Huang; Siyang Zhang; Qingfu Zhang; Jihong Chang; Xueshan Qiu; Enhua Wang
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

8.  MiR-125a-3p regulates glioma apoptosis and invasion by regulating Nrg1.

Authors:  Feng Yin; Jian Ning Zhang; Shu Wei Wang; Chun Hui Zhou; Ming Ming Zhao; Wen Hong Fan; Ming Fan; Shuang Liu
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

9.  LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer.

Authors:  Zhongbao Zhang; Jiajing Cheng; Yi Wu; Jin Qiu; Yi Sun; Xiaowen Tong
Journal:  Mol Med Rep       Date:  2016-07-28       Impact factor: 2.952

10.  High Expression of HULC Is Associated with Poor Prognosis in Osteosarcoma Patients.

Authors:  Vanessa Regina Maciel Uzan; André van Helvoort Lengert; Érica Boldrini; Valter Penna; Cristovam Scapulatempo-Neto; Carlos Alberto Scrideli; Alberto Paiva de Moraes Filho; Carlos Eduardo Bezerra Cavalcante; Cleyton Zanardo de Oliveira; Luiz Fernando Lopes; Daniel Onofre Vidal
Journal:  PLoS One       Date:  2016-06-02       Impact factor: 3.240

View more
  10 in total

Review 1.  Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.

Authors:  Dave N T Aryee; Valerie Fock; Utkarsh Kapoor; Branka Radic-Sarikas; Heinrich Kovar
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

2.  LncRNA HULC shRNA disinhibits miR-377-5p to suppress the growth and invasion of hepatocellular carcinoma in vitro and hepatocarcinogenesis in vivo.

Authors:  Chunxiao Yan; Shutang Wei; Dazheng Han; Liping Wu; Lixia Tan; Hangyu Wang; Yong Dong; Jing Hua; Wenyi Yang
Journal:  Ann Transl Med       Date:  2020-10

3.  Genome-wide identification of a competing endogenous RNA network in cholangiocarcinoma.

Authors:  Ganxun Li; Tongtong Liu; Bixiang Zhang; Weixun Chen; Zeyang Ding
Journal:  J Cell Biochem       Date:  2019-07-03       Impact factor: 4.429

4.  CircRNA ARFGEF1 functions as a ceRNA to promote oncogenic KSHV-encoded viral interferon regulatory factor induction of cell invasion and angiogenesis by upregulating glutaredoxin 3.

Authors:  Shuihong Yao; Xuemei Jia; Fei Wang; Liuxue Sheng; Pengxia Song; Yanhui Cao; Hongjuan Shi; Weifei Fan; Xiangya Ding; Shou-Jiang Gao; Chun Lu
Journal:  PLoS Pathog       Date:  2021-02-04       Impact factor: 6.823

Review 5.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

Review 6.  CircRNA ITCH: Insight Into Its Role and Clinical Application Prospect in Tumor and Non-Tumor Diseases.

Authors:  Tong Liu; Tao Huang; Mei Shang; Gang Han
Journal:  Front Genet       Date:  2022-07-15       Impact factor: 4.772

7.  Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis.

Authors:  Bo Huang; Min Wei; Li Hong
Journal:  Open Life Sci       Date:  2021-07-01       Impact factor: 0.938

8.  Quantitative proteomics analysis of glioblastoma cell lines after lncRNA HULC silencing.

Authors:  Shan Ye; Jing Wu; Yiran Wang; Yuchen Hu; Tiantian Yin; Jie He
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

9.  LPS promotes the progression of sepsis by activation of lncRNA HULC/miR-204-5p/TRPM7 network in HUVECs.

Authors:  Xinghai Chen; Debiao Song
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

10.  Potential role of lncRNA HULC/miR‑128‑3p/RAC1 axis in the inflammatory response during LPS‑induced sepsis in HMEC‑1 cells.

Authors:  Weize Yang; Xiaomin Luo; Yu Liu; Jun Xiong; Hongxia Xia; Yafeng Liu
Journal:  Mol Med Rep       Date:  2020-10-14       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.